Slynd
This website includes Slynd promotional information and is intended for UK healthcare professionals only.
For women who haven’t found the right fit yet…
Slynd® is the first oestrogen-free drospirenone POP in the UK.1,2
Slynd® is a progestogen-only pill (POP) indicated for contraception.1
Slynd® Recommended
Slynd® is a POP recommended as a contraceptive in the 2023 Faculty of Sexual and Reproductive Healthcare (FSRH) Guidelines and is covered by POP guidance in the UK Medical Eligibility Criteria (UKMEC).2-4
Slynd® Benefits
Properties of Drospirenone.
Drospirenone, which in therapeutic doses possesses mild anti-androgenic and anti-mineralcorticoid activity. 1,2
24+4 active/placebo.
A 24+4 active/placebo dose regimen with a hormone free interval (HFI) developed to support scheduled bleeding.1,5
Fewer Bleeding Days.
Significantly fewer unscheduled bleeding days per treatment cycle and a significantly lower study drop-out rate due to bleeding disorders vs. desogestrel 75 µg.*,6,7
Effective contraceptive.
Effective contraceptive protection when used correctly.1,8
24h window.
The only POP in the UK with a 24 hour missed pill window.1,2
Common AEs.
Libido disorder, mood disturbances, headache, nausea, abdominal pain, acne, breast discomfort, metrorrhagia, vaginal haemorrhage, dysmenorrhoea, menstruation irregular, and weight increased.1
* Bleeding days per treatment cycle: Cycle 2-4: desogestrel, 16.9 days (n=222) vs. drospirenone, 9.6 days (n=527), p <0.0001; Cycles 2-6: desogestrel, 23.7 days (n=172) vs. drospirenone, 13.7 days (n=422), p<0.0001; Cycle 2-9: desogestrel, 34.7 days (n=116) vs. drospirenone, 21.5 days (n=305), p=0.0003. Study drop-out rate due to abnormal uterine bleeding: desogestrel: 6.6% (n=332); drospirenone: 3.3% (n=858); p<0.05. 6,7
Download helpful materials about Slynd, designed to support you in providing the best care for your patients.
Missed pill?
Slynd® is the only POP in the UK with a 24 hour missed pill window.1,2
What Makes Slynd Different for Bleeding Control?
*Also, women experienced fewer mean days of unscheduled spotting/bleeding:
Cycle 2–4: Drospirenone 4 mg – 9.6 (n=858); Desogestrel 75 μg – 16.9 (n=332); p<0.0001;
Cycle 2–6: Drospirenone 4 mg – 13.7 (n=858); Desogestrel 75 μg – 23.7 (n=332); p<0.0001; Cycle 2–9: Drospirenone 4 mg – 21.5 (n=858); Desogestrel 75 μg – 34.7 (n=332); p=0.0003;
Cycle 7-9: Drospirenone 4 mg – 7.2 (n=858); Desogestrel 75 μg – 10.8 (n=332); p=0.0277
Understanding Slynd’s Safety and Tolerability
Slynd® has demonstrated an acceptable tolerability profile.1
Cost
£4.90
Abbreviations: AE, adverse event; FSRH, Faculty of Sexual and Reproductive Healthcare; HFI, hormone free interval; POP, progestogen-only pill; UKMEC, UK Medical Eligibility Criteria.
References: 1. Slynd® Summary of Product Characteristics. 2. FSRH Clinical Guidelines progestogen-only pills. 07/2025 3. UK Medical Eligibility Criteria. For Contraceptive Use. 2016 (Amended 2019). 4. FSRH CEU Statement. Drospirenone Progestogen-only Pill (DRSP POP). January 2024. Accessed: July 2025. 5. Archer, D.F., . 2015. 92:439-444. 6. Palacios, S., et al. Arch Gynae Obs. 2019. 300:1805-1812. 7. Palacios, S., et al. PLOS ONE. 2020. 15(6):e0231856. 8. Palacios, S., et al. BMC Women’s Health. 2020. 20:218. 9. Slynd® 4 mg tablets. NHS DM+D Browser. Accessed: July 2025
